Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28185035
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28185035
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Cardiovasc+Drugs+Ther
2017 ; 31
(1
): 63-75
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Anthracycline Chemotherapy and Cardiotoxicity
#MMPMID28185035
McGowan JV
; Chung R
; Maulik A
; Piotrowska I
; Walker JM
; Yellon DM
Cardiovasc Drugs Ther
2017[Feb]; 31
(1
): 63-75
PMID28185035
show ga
Anthracycline chemotherapy maintains a prominent role in treating many forms of
cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes
expose the cancer survivor to increased cardiovascular morbidity and mortality.
The basic mechanisms of cardiotoxicity may involve direct pathways for reactive
oxygen species generation and topoisomerase 2 as well as other indirect pathways.
Cardioprotective treatments are few and those that have been examined include
renin angiotensin system blockade, beta blockers, or the iron chelator
dexrazoxane. New treatments exploiting the ErbB or other novel pro-survival
pathways, such as conditioning, are on the cardioprotection horizon. Even in the
forthcoming era of targeted cancer therapies, the substantial proportion of
today's anthracycline-treated cancer patients may become tomorrow's cardiac
patient.
|Animals
[MESH]
|Anthracyclines/*adverse effects
[MESH]
|Antibiotics, Antineoplastic/*therapeutic use
[MESH]
|Cardiotoxicity
[MESH]
|Cardiovascular Agents/therapeutic use
[MESH]
|Cytoprotection
[MESH]
|Heart Diseases/*chemically induced/metabolism/physiopathology/prevention &
control
[MESH]